Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Söderlund-Venermo, K. Brown, D. Erdman (1987)
[Human parvoviruses].Annales de pediatrie, 34 7
LJ Anderson (1990)
Human parvoviruses.J Infect Dis, 161
P. Mortimer, N. Luban, J. Kelleher, B. Cohen (1983)
TRANSMISSION OF SERUM PARVOVIRUS-LIKE VIRUS BY CLOTTING-FACTOR CONCENTRATESThe Lancet, 322
M Maki, T Kobayashi, T Terao (2000)
Antithrombin therapy for severe preeclampsia: results of a double‐blind, randomized, placebo‐controlled trial.Thromb Haemost, 84
T. Yee, B. Cohen, K. Pasi, C. Lee (1996)
Transmission of symptomatic parvovirus B19 infection by clotting factor concentrateBritish Journal of Haematology, 93
B. Cohen, A. Field, S. Gudnadóttir, S. Beard, J. Barbara (1990)
Blood donor screening for parvovirus B19.Journal of virological methods, 30 3
T Weimer, S Streichert, C Watson (1998)
Validation of a PCR assay system to screen plasma for HBV, HCV, and HIV‐1.Infusionsther Transfusionsmed, 25
M. Ragni, W. Koch, J. Jordan (1996)
Parvovirus B19 infection in patients with hemophiliaTransfusion, 36
T. Schwarz (1994)
[Transmission of parvovirus B19 by blood and blood components].Infusionstherapie und Transfusionsmedizin, 21 Suppl 1
(1994)
[ Severe hematologic involvement in parvovirus B 19 infection
J. Hilfenhaus, A. Gröner, T. Nowak, T. Weimer (1997)
Analysis of human plasma products: polymerase chain reaction does not discriminate between live and inactivated virusesTransfusion, 37
F. Mcomish, P. Yap, A. Jordan, H. Hart, B. Cohen, P. Simmonds (1993)
Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reactionJournal of Clinical Microbiology, 31
J. Irwin (1953)
Statistical Method in Biological AssayNature, 172
(1999)
Guidelines for validation of nucleic acid amplification technology (NAT) for the detection of hepatitis C virus (HCV) RNA in plasma poolsVox Sang
E. Mauser-Bunschoten, H. Zaaijer, A. Drimmelen, S. Vries, G. Roosendaal, H. Berg, P. Lelie (1998)
High Prevalence of Parvovirus B19 lgG Antibodies among Dutch Hemophilia PatientsVox Sanguinis, 74
T. Weimer, S. Streichert, C. Watson (1998)
Validation of a PCR Assay System to Screen Plasma for HBV, HCV, and HIV-1Transfusion Medicine and Hemotherapy, 25
C. Jones (1963)
REGIONAL CURARISATION. ANAESTHESIA FOR SURGERY OF THE KNEE-JOINT.Lancet, 2 7306
K. Heermann, H. Seitz, R. Thomssen (1996)
Capture and RT-PCR of hepatitis C virus RNA with safety primers.Journal of virological methods, 59 1-2
A. Eis-Hübinger, U. Sasowski, H. Brackmann, R. Kaiser, B. Matz, K. Schneweis (1996)
Parvovirus B19 DNA Is Frequently Present in Recombinant Coagulation Factor VIII ProductsThrombosis and Haemostasis, 76
J. Saldanha, P. Minor (1996)
Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufactureBritish Journal of Haematology, 93
P. Koduri (1998)
Novel cytomorphology of the giant proerythroblasts of parvovirus B19 infectionAmerican Journal of Hematology, 58
Bunschoten, HL. Zaaijerb, Drimmelen, S. Vries, Roosendaal, HM. denBerg, RN. Lelieb (1998)
High Prevalence of Parvovirus B19 IgG Antibodies among Dutch Hemophilia PatientsVox Sanguinis, 74
Y. Yoto, T. Kudoh, K. Haseyama, N. Suzuki, Takanori Oda, T. Katoh, Tsuneo Takahashi, Sadami Sekiguchi, Shunzo Chiba (1995)
Incidence of human parvovirus B19 DNA detection in blood donorsBritish Journal of Haematology, 91
C. Woernle, L. Anderson, P. Tattersall, J. Davison (1988)
Human parvovirus B19 infection during pregnancy.The Journal of infectious diseases, 156 1
G. Kurtzman, N. Frickhofen, J. Kimball, D. Jenkins, A. Nienhuis, N. Young (1989)
Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy.The New England journal of medicine, 321 8
K. Brown, N. Young (1997)
Parvovirus B19 in human disease.Annual review of medicine, 48
C. Prowse, C. Ludlam, P. Yap (1997)
Human Parvovirus B19 and Blood ProductsVox Sanguinis, 72
C Prowse, CA Ludlam, PL Yap (1997)
Human parvovirus B19 and blood products.J Virol Methods, 72
M. Maki, Takao Kobayashi, T. Terao, Tsuyomu Ikenoue, K. Satoh, M. Nakabayashi†, Y. Sagara, Y. Kajiwara, Masao Urata (2000)
Antithrombin Therapy for Severe PreeclampsiaThrombosis and Haemostasis, 84
J. Lefrère, M. Mariotti, M. Thauvin (1994)
B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentratesThe Lancet, 343
B. Mosquet, J. Lacotte, A. Querrec, J. Petitjean, G. Grollier, M. Moulin (1994)
[Severe hematologic involvement in parvovirus B19 infection. Are antithrombin III injections the origin of the contamination?].Therapie, 49 5
Sanjay Tyagi, F. Kramer (1996)
Molecular Beacons: Probes that Fluoresce upon HybridizationNature Biotechnology, 14
A. Poblotzki, A. Hemauer, A. Gigler, E. Puchhammer-Stöckl, F. Heinz, J. Pont, K. Laczika, H. Wolf, S. Modrow (1995)
Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: implications for pathogenesis.The Journal of infectious diseases, 172 5
Takeshi Sasaki, C. Murai, T. Muryoi, Yuichi Takahashi, Y. Munakata, K. Sugamura, Keishi Abe (1995)
Persistent infection of human parvovirus B19 in a normal subjectThe Lancet, 346
BACKGROUND: Human parvovirus B19 (B19) is regarded as a potential risk factor for certain patient populations receiving plasma components.
Transfusion – Wiley
Published: Jan 1, 2001
Keywords: ; ; ;
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.